Journal article
Abstract 15586: Burden of Cardiovascular or Fatal Outcomes in People With Type 2 Diabetes and Cardiovascular Risk Factors Treated With Dulaglutide a Post Hoc Analysis From the Rewind Trial
Abstract
Introduction:
In the REWIND (Researching cardiovascular Events with a Weekly INcretin in Diabetes) trial, weekly subcutaneous dulaglutide 1.5 mg, a glucagon-like peptide-1 receptor agonist, compared with matched placebo reduced MACE (cardiovascular [CV] death, non-fatal myocardial infarction or non-fatal stroke) (594 versus 663 events) in 9901 participants with type 2 diabetes at moderate CV risk [mean (SD) age 66.2 (6.5) …
Authors
Dagenais G; Lakshmanan MC; Dyal L; Atisso CM; Colhoun H; Ryden LE; Gerstein HC
Journal
Circulation, Vol. 142, No. Suppl_3,
Publisher
Wolters Kluwer
Publication Date
November 17, 2020
DOI
10.1161/circ.142.suppl_3.15586
ISSN
0009-7322